ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03290534
Recruitment Status : Not yet recruiting
First Posted : September 25, 2017
Last Update Posted : September 25, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
CivaTech Oncology

Brief Summary:
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

Condition or disease Intervention/treatment Phase
Lung Cancer Lung Cancer Stage I Lung Cancer Stage II Device: CivaSheet Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Estimated Study Start Date : December 2017
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer


Intervention Details:
  • Device: CivaSheet
    implanting CivaSheet for localized radiation dose delivery
    Other Name: brachytherapy


Primary Outcome Measures :
  1. Local Control Rate at 1 year [ Time Frame: 1 year ]
    The local control rate in the region irradiated by CivaSheet.


Secondary Outcome Measures :
  1. Freedom from regional or distant recurrence [ Time Frame: 1 year ]
    Control rate for recurrences outside the local area irradiated by CivaSheet.

  2. Time to recurrence [ Time Frame: 1 year ]
    Time in months to any recurrence

  3. Toxicity graded on CTCAE 4.0 Scale [ Time Frame: 1 year ]
    pulmonary function, radiation pneumonitis, fatigue, lung fibrosis, etc.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject signed inform consent
  • Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
  • Pre-operative criteria
  • Lung nodule suspicious for NSCLC
  • Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
  • Clinical stage I or Clinical stage II
  • Not pregnant or nursing
  • Negative pregnancy test in premenopausal women
  • Fertile patients must use effective contraception
  • More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03290534


Contacts
Contact: Carra Castagnero 9193145515 clinical@civatechoncology.com
Contact: Kristy Perez, PhD 6789545744 kperez@civatechoncology.com

Sponsors and Collaborators
CivaTech Oncology
National Cancer Institute (NCI)

Responsible Party: CivaTech Oncology
ClinicalTrials.gov Identifier: NCT03290534     History of Changes
Other Study ID Numbers: CT006
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: September 25, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by CivaTech Oncology:
wedge resection
sublobar resection
brachytherapy
CivaSheet
Pd-103
CivaTech Oncology

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases